Gabriel Iglesias's Ozempic weight regain claim, fact-checked

What did @clubshayshaypod actually say?

Gabriel Iglesias told host Shay Shay that he used semaglutide (he calls it "ozemic" throughout) for about five months, lost weight, then stopped and "immediately gained back 20 pounds like that." He also claimed the drug causes you to "lose more muscle than fat," pointing to visible shoulder muscle loss as his evidence. He's not a doctor and he's not pretending to be one, but 18.9K people heard these claims, so they're worth examining closely.

He also dropped a side note that Ozempic approached him years ago with a million-dollar brand deal he turned down, which is unverifiable but irrelevant to the health claims. The part that matters medically: rapid rebound weight gain after stopping, and muscle loss being worse than fat loss on semaglutide.

Does the science back this up?

On weight regain after stopping, Iglesias is largely correct, and the data is striking. On the muscle loss claim, he's partially right but missing important context that changes the whole picture.

The STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) followed patients who stopped semaglutide after 68 weeks. Within one year of stopping, participants regained about two-thirds of their prior weight loss. That's not "immediately" in the clinical sense, but the trajectory starts fast, and anecdotally, five months on a lower dose with no lifestyle infrastructure built around it? Rapid regain is plausible.

On muscle loss: yes, GLP-1 agonists do cause loss of lean mass. A 2023 analysis by Bikou et al. in Obesity Reviews confirmed that roughly 25-39% of total weight lost on semaglutide can come from lean mass. But here's the thing Iglesias missed entirely: that same ratio applies to almost any caloric restriction method. The muscle loss isn't uniquely worse on Ozempic compared to dieting alone. Resistance training and adequate protein intake are the known mitigating factors, and there's no indication he used either.

What did they get wrong (or right)?

Iglesias gets credit for the rebound claim. It's real, it's documented, and most people on social media still don't understand that semaglutide is not a short-term fix you stop when the weight is gone. He got that right, even if his "immediately" framing is a bit dramatic.

The muscle loss framing is where he stumbles. Saying "you're gonna lose more muscle than fat" is not accurate as a blanket statement. Studies show lean mass loss is a real concern, but fat mass loss is still typically the dominant component of total weight lost on semaglutide. Paluch et al. (2023, JAMA Network Open) noted that without protein intake optimization and resistance exercise, lean mass loss increases, but it's not the majority of what's lost in most cases.

The bigger problem: he presents muscle loss as a reason to stop the medication, rather than a reason to add protein and strength training while on it. That's a meaningful difference. Stopping a medication because of a side effect that has known behavioral mitigations is a different conversation than one where there's no recourse.

What should you actually know?

Weight regain after stopping GLP-1 medications is not a bug or a mystery. It reflects that the drug is actively suppressing appetite, and when you remove it, hunger and metabolic rate largely return to baseline. The STEP 4 trial (Rubino et al., 2021, JAMA) showed that patients who continued semaglutide kept losing weight while those who switched to placebo regained significantly. This is why most endocrinologists treat it as a chronic condition requiring ongoing management, not a course of antibiotics you finish and move on from.

On muscle loss: the American College of Sports Medicine and multiple obesity medicine specialists recommend combining GLP-1 therapy with resistance training and hitting at least 1.2-1.6 grams of protein per kilogram of body weight daily. These aren't optional add-ons. They're the difference between losing fat and losing the muscle you'll want when the weight is gone.

If you're considering stopping semaglutide, that decision should involve a clinician, not a TikTok clip. Rapid discontinuation without a maintenance plan is exactly the scenario that produces the kind of fast rebound Iglesias described.